



Linkage of Whole Genome Sequencing, Epidemiological, and Clinical Data to Understand the Genetic Diversity and Clinical Outcomes of *Shigella flexneri* among Men Who Have Sex with Men in England

Holly D. Mitchell,^{a,b} Nicholas R. Thomson,^{c,d} Claire Jenkins,^{e,f} Timothy J. Dallman,^{e,f} Anaïs Painset,^{e,f} Peter Kirwan,^e Valerie Delpech,^e Amy F. W. Mikhail,^e Nigel Field,^a Gwenda Hughes^{b,e}

^aCentre for Molecular Epidemiology and Translational Research, Institute for Global Health, University College London, London, UK

^bThe National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London, London, UK

^cParasites and Microbes, Wellcome Trust Sanger Institute, Hinxton, UK

^dDepartment of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London, UK

^eNational Infection Service, Public Health England, London, UK

^fThe National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool, Liverpool, UK

Nigel Field and Gwenda Hughes contributed equally to this article. Author order was determined by supervisory role.

ABSTRACT The public health value of whole genome sequencing (WGS) for *Shigella* spp. in England has been limited by a lack of information on sexual identity and behavior. We combined WGS data with other data sources to better understand *Shigella flexneri* transmission in men who have sex with men (MSM). WGS data for all *S. flexneri* isolates referred to the national reference laboratory were linked to i) clinical and behavioral data collected in seven of 21 health regions in England using a standardized exposure questionnaire and, ii) national HIV surveillance data. We included 926 *S. flexneri* isolates, of which 43.0% ($n = 398$) fell phylogenetically within two domestically circulating clades associated with genotypic markers of azithromycin resistance. Approximately one third of isolates in these clades were from people living with HIV, primarily acquired through sex between men. 182 (19.7%) isolates had linked questionnaire data; 88% (84/95) of MSM isolates fell phylogenetically within the domestically circulating clades, while 92% (72/78) of isolates from other cases fell within lineages linked with travel to high-risk regions. There was no evidence of sustained transmission between networks of MSM and the wider community. MSM were more likely to be admitted to hospital and receive antimicrobials. Our study emphasizes the importance of sex between men as a major route of transmission for *S. flexneri*. Combined WGS, epidemiological and clinical data provide unique insights that can inform contact tracing, clinical management and the delivery of targeted prevention activities. Future studies should investigate why MSM experience more severe clinical outcomes.

IMPORTANCE Within the last 2 decades there have been an increasing number of *Shigella* spp. outbreaks among men who have sex with men (MSM) worldwide. In 2015, Public Health England (PHE) introduced routine whole genome sequencing (WGS) for the national surveillance of *Shigella* spp. However, the lack of information on sexual identity and behavior has hindered interpretation. Our study illustrates the power of linking WGS data with epidemiological, behavioral, and clinical data. We provide unique population-level insights into different transmission networks that can inform the delivery of appropriate public health interventions and patient management. Furthermore, we describe and compare clinical characteristics and

Editor Swaine L. Chen, The National University of Singapore and the Genome Institute of Singapore

© Crown copyright 2021. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Holly D. Mitchell, holly.mitchell.16@ucl.ac.uk, or Claire Jenkins, claire.jenkins1@phe.gov.uk.

Received 1 October 2021

Accepted 3 November 2021

Published 15 December 2021

outcomes of *S. flexneri* infection in MSM and other exposure groups. We found that MSM were more likely to be admitted to hospital and receive antimicrobials, indicating that their infections were potentially more severe. The exact reasons for this are unclear and require further exploration.

KEYWORDS whole genome sequencing, surveillance, England, *Shigella*, men who have sex with men

S *Shigella* spp. (*Shigella flexneri*, *Shigella dysenteriae*, *Shigella sonnei*, and *Shigella boydii*) are Gram-negative bacteria and the most common cause of severe dysentery globally (1, 2). Transmission occurs via the fecal-oral route through direct contact with an infected person, or exposure to contaminated surfaces, food, or water. In high-income countries, cases are often linked with travel to regions with poor food and water hygiene, primarily South Asia or sub-Saharan Africa. Sexual transmission can also occur through direct oral-anal contact or through oral sex after sex, via fingers or fomites (3). Within the last 2 decades, *S. flexneri* and *S. sonnei* outbreaks among men who have sex with men (MSM) have become more frequent globally, often associated with antimicrobial resistance (4–9).

Shigellosis cases in England have historically been associated with travel to high-risk regions or person-to-person transmission in household or childcare settings (10, 11). However, since 2009, there have been successive increases of *S. flexneri* (serotypes 2a and 3a) and *S. sonnei* in adult men reporting no recent foreign travel, while cases in adult men reporting foreign travel, and in women, have remained relatively stable (4, 12, 13). While suggestive of sexual transmission in MSM, the lack of data on sexual identity and behavior has hindered interpretation, with only one small qualitative study in 2012 providing supportive evidence (7). Our previous genomic studies have relied primarily on sex, age, and foreign travel history information to describe *Shigella* spp. sublineages likely being sexually transmitted among MSM (5, 14).

In 2015, to address the lack of evidence for sexual transmission and to inform infection control measures, Public Health England (PHE) piloted a questionnaire to standardize and expand the collection of exposure information on suspected shigellosis cases, including questions on sexual identity and behavior. Concurrently, whole genome sequencing (WGS) was routinely implemented for all *Shigella* spp. isolates referred to the national reference laboratory (15, 16). Previously we showed how these data might be used to distinguish *S. flexneri* clusters linked through sexual and nonsexual transmission in near real-time (6). Here, we describe the characteristics and genetic diversity of *S. flexneri* transmission through sex between men, assess any potential overlap with nonsexual transmission, and explore clinical outcomes.

RESULTS

Summary of isolates and linked data. Between August 2015 and July 2017, 926 *S. flexneri* clonal complex (CC) 245 isolates were referred to the reference laboratory and sequenced. Questionnaire data were available for 182 (19.7%), of which over half (52.2%; $n = 95$) were MSM, 33.5% ($n = 61$) were other adults (heterosexual men or adult women), 9.3% ($n = 17$) were children and 5.0% ($n = 9$) were adult men who did not provide sexual identity or recent behavior information. Data linkage to HIV and AIDS Reporting System (HARS) revealed that 18.7% (173/926) of *S. flexneri* isolates were taken from people living with HIV (PLWH) (Supplementary File 3).

Isolates with linked questionnaire data represented 38.4% (182/473) of all *S. flexneri* CC245 isolates referred to the reference laboratory from HPTs participating in the pilot of the questionnaire and 22.8% (182/800) of all isolates referred nationally during the pilot period (August 2015 to March 2017) (Supplementary File 3).

Compared to all isolates included in the study without questionnaire data ($n = 744$), a higher proportion of isolates with linked questionnaire data ($n = 182$) were from cases living in London, adults aged 25–34 years, and cases who had not traveled abroad (Supplementary File 4).




FIG 1 Phylogeny of *S. flexneri* CC245 isolates. Midpoint rooted maximum likelihood phylogenetic tree showing a single representative from each 10-SNP single linkage cluster (N = 474) for CC245 during the study period and seven reference strains for each phylogenetic group (27). The number of isolates represented by each tip (i.e., the number of cases within each 10-SNP single linkage cluster) ranges from 1 to 240. Clusters with two or more cases are shown as a colored track on the outside of the tree according to size range (inner track). Region of travel in the past 4 days (middle track) and genotypic markers of azithromycin resistance (outer track) are also shown as colored tracks on the outside of the tree. Isolates belonging to MSM and non-MSM (as reported in the questionnaire) are shown as stars on the branches, where each star indicates that at least one isolate from that cluster was MSM or non-MSM. Domestically circulating clades (referred to in the text as PG1 and PG3) are highlighted in gray: Top clade PG1 (serotype 3a) median pairwise SNP distance 37, minimum 0, maximum 165; bottom clade PG3 (serotype 2a) median pairwise SNP distance 21, minimum 0, maximum 47.

Genetic diversity. Phylogenetic analysis highlighted two domestically circulating clades first described by Baker et al. (2015, 2018) (5, 14) that were presumed to be associated with transmission through sex between men (Fig. 1); one phylogenetic clade within *S. flexneri* phylogenetic group 1 (PG1) serotype 3a and a second phylogenetic clade within PG3 serotype 2a (herein 'PG1 and PG3'). These two clades accounted for 43.0% (398/926) of all isolates in this study. Where recorded, 97.5% (384/394) of PG1 and PG3 isolates were from adult men (≥ 18 years), 1.5% (6/394) were from adult women and 1.0% (4/394) were from children.

Among isolates from MSM (reported through the questionnaire), 88.4% (84/95) belonged to PG1 and PG3 (Fig. 1, Table 1). The remaining 11.6% (11/95) were dispersed throughout the phylogeny within lineages that were predominantly linked with travel to high-risk regions (here, "travel-associated lineages"). Six of 27 men self-identifying as heterosexual and seven of nine men not providing sexual identity or behavior information had isolates that were phylogenetically located within PG1 and PG3. Among the six heterosexual-identifying men, three reported recent sexual contact with a woman, one reported no recent sexual contact, and two provided no information.

Azithromycin resistance. Overall, 40.0% (370/926) of isolates harbored *mphA* and/or *ermB* genes, known to confer azithromycin resistance. 89.2% (330/370) of these isolates fell phylogenetically within PG1 and PG3 and the remaining 10.8% (40/370) belonged to multiple other distinct phylogenetic branches (Fig. 1).

Among isolates with linked questionnaire data, 83.2% (79/95) of isolates from MSM carried *mphA* and/or *ermB* compared to only 7.7% (6/78) of isolates from non-MSM

TABLE 1 Selected epidemiological and molecular characteristics for *S. flexneri* cases with questionnaire data^a

Characteristic	MSM N = 95	Other adults N = 61	Children N = 17	Not known N = 9
Sex				
Male	95 (100)	27 (44.3)	9 (52.9)	9 (100)
Female	0	34 (55.7)	8 (47.1)	0
Age group				
<18	0	0	17 (100)	0
18–24	8 (8.4)	6 (9.8)	0	1 (11.1)
25–34	33 (34.7)	24 (39.3)	0	0
35–44	25 (26.3)	8 (13.1)	0	3 (33.3)
45–64	28 (29.5)	17 (27.9)	0	5 (55.6)
65+	1 (1.1)	6 (9.8)	0	0
Ethnic group				
White	70 (79.6)	22 (40.7)	2 (12.5)	5 (100)
Asian or Asian British	3 (3.4)	18 (33.3)	11 (68.8)	0
Other	15 (17.1)	14 (25.9)	3 (18.8)	0
Not specified	7	7	1	4
Recent foreign travel history (past 4 days)^b				
South Asia	0	18 (29.5)	9 (52.9)	0
Sub-Saharan Africa	0	17 (27.9)	2 (11.8)	0
Europe	10 (10.5)	1 (1.6)	1 (5.9)	1 (11.1)
Caribbean, Central and South America	1 (1.1)	5 (8.2)	0	0
Middle East	1 (1.1)	2 (3.3)	1 (5.9)	1 (11.1)
North Africa	0	3 (4.9)	1 (5.9)	0
Other Asia	0	1 (1.6)	0	0
No/not specified ^b	83 (87.4)	14 (23.0)	3 (17.7)	7 (77.8)
Sexual identity (n = 165)				
Gay man	92 (98.9)	0	-	0
Bisexual man	1 (1.1)	0	-	0
Heterosexual man	0	27 (50.0)	-	0
Heterosexual woman	0	27 (50.0)	-	0
Not specified	2 ^c	7 ^d	-	9
Recent sexual contact (n = 131)				
Yes – with man	68 (72.3)	0	-	0
Yes – with woman	0	12 (50.0)	-	0
Yes – sex of partner not disclosed	0	0	-	2 (33.3)
No	26 (27.7)	12 (50.0)	-	4 (66.7)
Not specified	1	3	-	3
IMD quintile of deprivation				
1 (Most deprived)	40 (42.1)	20 (32.8)	5 (29.4)	1 (12.5)
2	38 (40.0)	20 (32.8)	8 (47.1)	6 (75.0)
3	9 (9.5)	14 (23.0)	2 (11.8)	0
4	3 (3.2)	4 (6.6)	2 (11.8)	1 (12.5)
5 (Least deprived)	5 (5.3)	3 (4.9)	0	0
Not specified	0	0	0	1
Occupation				
School/nursery child	0	0	17 (100)	0
Health care ^e	8 (8.9)	1 (1.8)	0	1 (12.5)
Social care/nursery worker ^e	3 (3.4)	4 (7.3)	0	0
Food handler/catering ^e	8 (8.9)	6 (10.9)	0	0
Fitness/gym worker	0	2 (3.6)	0	0
Travel industry	2 (2.2)	0	0	0
Other	55 (61.1)	34 (61.8)	0	6 (75.0)
Not working/retired	14 (15.6)	8 (13.1)	0	1 (12.5)
Not specified	5	6	0	1
Serotype				
2a	73 (86.9)	27 (45.8)	10 (62.5)	5 (55.6)
Other	11 (13.1)	32 (54.2)	6 (37.5)	4 (44.4)
Not specified	11	2	1	0

(Continued on next page)

TABLE 1 (Continued)

Characteristic	MSM N = 95	Other adults N = 61	Children N = 17	Not known N = 9
Phylogenetic lineage/clade				
PG3, serotype 2a	71 (74.7)	5 (8.2)	0	5 (55.6)
PG1, serotype 3a	13 (13.7)	1 (1.6)	0	2 (22.2)
Travel-associated lineage	11 (11.6)	55 (90.2)	17 (100)	2 (22.2)
Genotypic markers of azithromycin resistance				
<i>mphA</i> and <i>ermB</i>	71 (74.7)	5 (8.2)	0	5 (55.6)
<i>mphA</i> only	4 (4.2)	1 (1.6)	0	1 (11.1)
<i>ermB</i> only	4 (4.2)	0	0	0
None	16 (16.8)	55 (90.2)	17 (100)	3 (33.3)
HIV status at <i>Shigella</i> diagnosis				
HIV diagnosed >6 wks previously	45 (47.9)	3 (4.9)	0	2 (22.2)
HIV diagnosed within 6 wks	3 (3.2)	0	0	0
HIV diagnosed >6 wks after	1 (1.1)	0	0	0
Living with HIV but diagnosis date not known	1 (1.1)	0	0	0
HIV negative/unknown	45 (47.9)	58 (95.1)	17 (100)	7 (77.8)

^aN = 182 unless specified otherwise; denominator for sexual identity includes adults aged 18 years or older and the denominator for recent sexual contact (past 4 days prior to symptoms) includes adult men aged 18 years or older only. Missing data excluded from percentage calculations except for recent foreign travel history. IMD, Index of Multiple Deprivation; PG, phylogenetic group; MSM, men who have sex with men.

^bRecent foreign travel (past 4 days prior to symptoms) as recorded on questionnaire; data missing for 1 case.

^cSexual identity not specified for two men, but recent same-sex sexual contact reported.

^dSexual identity not specified for 7 adult women.

^eOccupation indicates the patient belongs to a recognized risk group and poses an increased risk of spreading their infection to others.

cases ($P < 0.001$) (Fig. 1, Table 1). The latter were from heterosexual-identifying men whose isolates fell phylogenetically within PG1 and PG3.

Overlap between *Shigella* and HIV. Among all *S. flexneri* isolates taken from PLWH; 98.3% (170/173) were from adult men and 1.7% (3/173) three were from adult women (Table 2). Among PLWH, 86.1% (149/173) had isolates that fell within PG1 and PG3. All these cases were adult men, and the probable route of HIV exposure was sex between men for 90.6% (135/149), heterosexual contact for 4.7% (7/149), injecting drug use for 1.3% (2/149) and unknown for 3.4% (5/149). Of all *S. flexneri* isolates within PG1 and PG3, 37.4% (149/398) were from PLWH.

Characteristics of cases with a questionnaire. Among cases with questionnaire data, MSM were less likely to report recent foreign travel compared to non-MSM (12.6% [12/95] versus 78.2% [61/78], $P < 0.001$) (Table 1). Most MSM reporting recent foreign travel had visited Europe (83.3%, $n = 10/12$) whereas most non-MSM reporting recent foreign travel had visited other regions (98.4%, $n = 60/61$), predominantly South Asia (44.3%, $n = 27/61$) or sub-Saharan Africa (31.1%, $n = 19/61$). Most MSM reported recent sex with a same-sex partner (72.3%, $n = 68/94$), of whom 13.2% (9/68) had also traveled, mainly to Europe ($n = 7$). Among MSM without recent sexual contact (27.7% [26/94]), only two had recently traveled and this was to Europe. Most MSM were White (79.6% [70/94]), whereas 41.4% (29/70) of non-MSM were Asian ethnicity and 34.3% (24/70) were White ($P < 0.001$). Half (47/95) of MSM were living with diagnosed HIV at the time of *S. flexneri* diagnosis. Where available, 80.8% (21/26) had an undetectable viral load (≤ 50 c/ml) and 81.2% (18/21) had a CD4 count > 350 cells/mm³.

Novel strain transmission among MSM. In addition to PG1 and PG3, the phylogenetic tree revealed new lineages suggestive of sexual transmission between men, most notably one exemplar cluster within PG2 (Table 3). Phylogenetic analysis of isolates within this cluster, contextualized using phylogenetically proximate isolates within 50 SNPs, revealed a previously unrecognized probable MSM clade (Fig. 2). All isolates within this clade were from adult men, most of whom had not traveled abroad (87.5%; 14/16), and most harbored genotypic markers of azithromycin resistance (87.5%; 14/16). Five were from men living with HIV, four of whom probably acquired HIV through sex between men. Questionnaire data were available for two adult men in this clade: One self-identified as gay and the other reported recent sexual contact but did not disclose their sexual identity or sex of their partner. In contrast, proximal isolates outside

TABLE 2 Epidemiological and molecular characteristics among *S. flexneri* cases living with HIV^a

Characteristic	MSM clade (N = 149)	Travel-associated lineage (N = 24)
Sex		
Man	149 (100)	21 (87.5)
Woman	0	3 (12.5)
Age group		
18–24	8 (5.4)	0
25–34	40 (26.9)	3 (12.5)
35–44	57 (38.3)	5 (20.8)
45–64	44 (29.5)	16 (66.7)
Recent foreign travel		
Yes	7 (4.7)	7 (29.2)
No/not specified	142 (95.3)	17 (70.8)
Sexual identity (n = 55)		
Gay man	44 (93.6)	5 (83.3)
Bisexual man	1 (2.1)	0
Heterosexual man	2 (4.3)	1 (16.7)
Not specified	2	0
Probable route of exposure to HIV		
Sex between men	135 (93.8)	16 (76.2)
Injecting drug use	2 (1.4)	0
Heterosexual contact – man	7 (4.9)	3 (14.3)
Heterosexual contact – woman	0	2 (9.5)
Not known	5	3
HIV status at time of <i>S. flexneri</i> diagnosis		
HIV diagnosed more than 6 wks previously	131 (88.5)	21 (87.5)
HIV diagnosed within previous 6 wks	4 (2.7)	1 (4.2)
HIV diagnosed within 6 wks after	3 (2.0)	2 (8.3)
HIV diagnosed more than 6 wks after	10 (6.8)	0
Living with HIV but diagnosis date not known	1	0
CD4 count (cells/mm ³)		
≤350	14 (16.7)	3 (20.0)
>350	70 (83.3)	12 (80.0)
Not known	65	9
Viral load (c/ml)		
≤50	74 (77.9)	13 (76.5)
>50	21 (22.1)	4 (23.5)
Not known	54	7

^aN = 173 unless otherwise specified. Sexual identity only available for people with a questionnaire (n = 55).

Missing data excluded from percentage calculations, except for recent foreign travel. Recent foreign travel (past 4 days prior to symptom onset) as recorded on questionnaire or on laboratory request forms for people who did not have a questionnaire. MSM, men who have sex with men.

this clade were from a mixed group of adult men, women, and children, most of whom reported recent travel to a high-risk region (92.3%; 12/13), and none harbored genotypic markers of azithromycin resistance. Questionnaire data were available for an adult female and a child who had recently traveled to South Asia, and the Middle East, respectively.

Clinical characteristics and outcomes. Clinical characteristics for cases with questionnaire data are presented in Table 4. Among adults who reported receiving antimicrobials, the class was available for 59.3% (67/113). Most reported receiving ciprofloxacin alone (51.1% [22/43] for MSM, 76.2% [16/21] for other adults, and all three adults whose sexual identity and behavior were not reported). Nine MSM received more than one antimicrobial, of whom seven received ciprofloxacin in combination with at least one other antimicrobial, up to a maximum of three. Six MSM received azithromycin (azithromycin only [n = 3], azithromycin and doxycycline [n = 2], azithromycin and ciprofloxacin [n = 1]); all had isolates harboring genotypic markers of azithromycin resistance.

TABLE 3 Epidemiological and molecular characteristics of 10-SNP clusters nested within travel-associated lineages and containing isolates from men who have sex with men^a

10-SNP cluster	PG (serotype)	MSM cases	Non-MSM	Total cases in cluster	Males: Females in cluster	Foreign travel	<i>mphA</i> and/or <i>ermB</i>	Living with HIV ^b
78.324.644.966.1208.%	1 (3a)	1	0	2	2:0	0	1	1
3.47.85.237.397.%	2 (1c)	1	0	10	10:0	2 ^c	10	3
4.49.69.337.364.%	3 (2a)	2	0	2	2:0	1	0	0
4.49.69.307.330.%	3 (2a)	1	0	2	2:0	0	2	2
4.49.69.95.615.%	3 (2a)	1	1	1	1:0	0	0	1
4.49.49.281.297.%	3 (2a)	1	1	2	2:0	0	0	0
4.110.188.317.439.%	3 (2a)	1	1	2	2:0	0	2	1
4.110.162.273.287.%	3 (2a)	1	1	2	2:0	0	2	1
4.184.304.462.531.%	3 (2a)	1	1	1	1:0	0	0	0
42.115.171.292.308.%	3 (2a)	1	1	1	1:0	0	1	1

^aA single representative from each 10-SNP cluster was presented in Fig. 1. MSM cases (n = 11) as reported on questionnaire. Non-MSM cases (n = 6) as reported on questionnaire. Clusters with one case indicate that the isolate did not cluster with another isolate at the 10-SNP threshold. Exemplar cluster showing a strong signal of an unrecognized lineage that is being transmitted in probable MSM is highlighted in gray (3.47.85.237.397.%). PG, phylogenetic group; MSM, men who have sex with men.

^bWhere reported, probable exposure to HIV was reported as sex between men.

^cTravel destination not recorded for one case.

Hospital admission was reported in 29.1% (48/165) of adults and was positively associated with: being MSM (aOR MSM versus non-MSM: 2.20 [95% CI: 1.02 to 4.73]; $P = 0.038$), *S. flexneri* serotype 2a (aOR all other serotypes versus serotype 2a: 0.28 [95% CI: 0.11 to 0.72], $P = 0.004$), and no recent foreign travel (aOR foreign travel versus no foreign travel: 0.34 [95% CI: 0.15 to 0.75]; $P = 0.005$) (Table 5). There was no evidence for an association between hospital admission and HIV status. Antimicrobial use was positively associated with: being MSM (aOR MSM versus non-MSM: 3.27 [95% CI: 1.62 to 6.63]; $P < 0.001$), *S. flexneri* belonging to PG1 or PG3 (aOR travel-associated lineage versus PG1/PG3: 0.46 [95% CI: 0.23 to 0.91]), *S. flexneri* harboring genotypic markers of azithromycin resistance (aOR: 2.82 [95% CI: 1.41 to 5.64]; $P = 0.003$), no recent foreign travel (aOR foreign travel versus no foreign travel: 0.35 [95% CI: 0.18 to 0.69]; $P = 0.002$), being of White ethnicity (aOR ethnic minority group versus White: 0.26 [95% CI: 0.12 to 0.54]; $P < 0.001$), and living with HIV (aOR: 2.15 [95% CI: 1.00 to 4.64]; $P = 0.043$).




FIG 2 Detection of novel strain transmission among MSM. Midpoint rooted maximum likelihood phylogenetic tree of all isolates from one selected single lineage cluster at the 50-SNP threshold nested within a travel-associated lineage (phylogenetic group 2, serotype 1c, SNP address 3.47.85.%, $n = 29$). Epidemiological data are represented as colored strips (age group, sex, genotypic markers of azithromycin resistance, region of travel) or as symbols on the branches (*S. flexneri* exposure group, ethnic group). Symbols are presented for people that have questionnaire data only. The clade associated with novel strain transmission in probable MSM is highlighted in gray ($n = 16$).

TABLE 4 Clinical characteristics, antimicrobial treatment, and health-seeking behavior among *S. flexneri* cases with questionnaire data^a

	MSM N = 95	Other adults N = 61	Children N = 17	Not known ^b N = 9
Previously heard of shigellosis ^c				
No	55 (64.0)	50 (87.7)	13 (92.9)	5 (83.3)
Yes	31 (36.0)	7 (12.3)	1 (7.1)	1 (16.7)
Not specified	9	4	3	3
Healthcare received				
GP	32 (34.8)	36 (62.1)	6 (37.5)	4 (57.1)
Hospital	28 (30.4)	9 (15.5)	3 (18.8)	2 (28.6)
Sexual Health/HIV clinic	13 (14.1)	1 (1.7)	0 (0)	1 (14.3)
GP & Hospital	12 (13.0)	12 (20.7)	7 (43.8)	0 (0)
GP, Hospital & Sexual Health/HIV clinic	7 (7.6)	0 (0)	0 (0)	0 (0)
Not specified	3	3	1	2
Diarrhoea				
No	1 (1.1)	1 (1.7)	0	0
Yes	92 (98.9)	59 (98.3)	16 (100)	9 (100)
Not specified	2	1	1	0
Abdominal pain				
No	6 (7.1)	6 (10.3)	4 (26.7)	1 (12.5)
Yes	78 (92.9)	52 (89.7)	11 (73.3)	7 (87.5)
Not specified	11	3	15	1
Vomiting				
No	54 (66.8)	36 (69.2)	6 (33.3)	4 (50.0)
Yes	27 (33.3)	16 (30.8)	10 (66.7)	4 (50.0)
Not specified	14	9	2	1
Fever				
No	17 (19.5)	20 (38.5)	3 (17.7)	2 (28.6)
Yes	80 (80.5)	32 (61.5)	14 (82.4)	5 (71.4)
Not specified	8	9	0	2
Mucus in stools				
No	31 (43.1)	34 (70.8)	5 (50.0)	3 (37.5)
Yes	41 (56.9)	14 (29.2)	5 (50.0)	5 (62.5)
Not specified	23	13	7	1
Blood in stools				
No	25 (29.4)	29 (52.7)	9 (69.2)	4 (50.0)
Yes	60 (70.6)	26 (47.3)	4 (30.8)	4 (50.0)
Not specified	10	6	4	1
Admitted to hospital				
No	55 (62.5)	46 (79.3)	9 (56.3)	6 (66.7)
Yes	33 (37.5)	12 (20.7)	7 (43.8)	3 (33.3)
Not specified	7	3	1	0
Antimicrobials prescribed				
No	18 (19.6)	25 (43.9)	0 (0)	1 (12.5)
Yes	74 (80.4)	32 (56.1)	16 (100.0)	7 (87.5)
Not specified	3	4	1	1

^aN = 182. Missing data excluded from percentage calculations. MSM, Men who have sex with men.

^bNot known includes adult men who did not provide information on sexual identity or recent sexual behavior.

^cBased on the question: Has the person heard of shigellosis/*shigella* spp. before?

DISCUSSION

We describe the largest study of shigellosis in England and build on previous studies by providing more comprehensive data on sexual identity and behavior, and by describing and comparing clinical characteristics and outcomes in MSM and other exposure groups. By including all *S. flexneri* CC245 isolates that were referred to the reference laboratory over a 2-year period, our findings are generalizable nationally. We show that most *S. flexneri* isolates from MSM belonged to two domestically circulating clades (PG1 and PG3) and the majority harbored genotypic markers of azithromycin resistance. We also identified a new lineage associated with transmission through sex between

TABLE 5 Characteristics associated with hospital admission and antimicrobial use in adults diagnosed with *S. flexneri* and with linked questionnaire data^a

	Hospital admission			Antimicrobial use		
	n/N (%)	OR (95% CI)	aOR (95% CI)	n/N (%)	OR (95% CI)	aOR (95% CI)
Exposure group (N = 156)						
Non-MSM	12/61 (19.7)	1.00	1.00	32/61 (52.5)	1.00	1.00
MSM	33/95 (34.7)	2.17 (1.02-4.65)	2.20 (1.02-4.73)	74/95 (77.9)	3.19 (1.59-6.42)	3.27 (1.62-6.63)
P value		0.039	0.038			<0.001
HIV status (N = 164)						
Negative/unknown	30/112 (26.8)	1.00	1.00	71/112 (63.4)	1.00	1.00
Living with HIV	17/52 (32.7)	1.33 (0.65-2.71)	1.33 (0.65-2.71)	41/52 (78.9)	2.15 (1.00-4.64)	2.15 (1.00-4.65)
P value		0.439	0.443			0.043
Serotype (N = 152)						
2a	36/105 (35.0)	1.00	1.00	72/105 (68.6)	1.00	1.00
Other	6/47 (12.8)	0.28 (0.11-0.72)	0.28 (0.11-0.72)	30/47 (63.8)	0.81 (0.39-1.67)	0.81 (0.39-1.67)
P value		0.004	0.004			0.567
Phylogenetic lineage/clade (N = 165)						
PG1/PG3	31/97 (32.0)	1.00	1.00	73/97 (75.3)	1.00	1.00
Travel-associated lineage	17/68 (25.0)	0.71 (0.35-1.42)	0.71 (0.35-1.45)	40/68 (58.8)	0.47 (0.24-0.92)	0.46 (0.23-0.91)
P value		0.330	0.346			0.025
Azithromycin resistance (N = 165)						
No	21/74 (28.4)	1.00	1.00	42/74 (56.8)	1.00	1.00
Yes	27/91 (29.7)	1.06 (0.54-2.09)	1.05 (0.52-2.09)	71/91 (78.0)	2.70 (1.38-5.32)	2.82 (1.41-5.64)
P value		0.856	0.897			0.003
Foreign travel (N = 165)						
No/unknown	38/104 (36.5)	1.00	1.00	80/104 (76.9)	1.00	1.00
Yes	10/61 (16.4)	0.34 (0.16-0.75)	0.34 (0.15-0.75)	33/61 (54.1)	0.35 (0.18-0.70)	0.35 (0.18-0.69)
P value		0.005	0.005			0.002
Age group (N = 165)						
18-24	3/15 (20.0)	0.68 (0.18-2.61)	0.68 (0.18-2.61)	10/15 (66.7)	0.86 (0.27-2.75)	0.86 (0.27-2.75)
25-34	20/57 (35.1)	1.47 (0.72-3.00)	1.47 (0.72-3.00)	38/57 (66.7)	0.86 (0.42-1.75)	0.86 (0.42-1.75)
≥35	25/93 (26.9)	1.00	1.00	65/93 (69.9)	1.00	1.00
P value		0.401	0.401			0.907
Per yr (age as a continuous variable)						
P value (age as a continuous variable)		1.00 (0.97-1.02)	1.00 (0.97-1.02)		1.00 (0.97-1.02)	1.00 (0.97-1.02)
		0.793	0.793			0.930
Ethnic group (N = 147)						
White	26/97 (26.8)	1.00	1.00	77/97 (79.4)	1.00	1.00
Ethnic minorities	17/50 (34.0)	1.41 (0.67-2.94)	1.42 (0.68-2.97)	25/50 (50.0)	0.26 (0.12-0.55)	0.26 (0.12-0.54)
P value		0.367	0.358			<0.001
IMD quintile (N = 164)						
1-2 (Most deprived)	37/125 (29.6)	1.00	1.00	85/125 (68.0)	1.00	1.00
3	8/23 (34.8)	1.27 (0.50-3.24)	1.28 (0.50-3.32)	17/23 (73.9)	1.33 (0.49-3.64)	1.34 (0.48-3.68)
4-5 (Least deprived)	3/16 (18.8)	0.55 (1.15-2.04)	0.56 (0.15-2.08)	11/16 (68.8)	1.04 (0.34-3.18)	1.04 (0.33-3.21)
P value		0.531	0.534			0.850

^aTotal numbers vary for each question due to missing data. Unadjusted and age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) calculated using logistic regression. Models adjusted for age as a continuous variable. P values by likelihood ratio test. Reference category for age group is aged 35 years and over. MSM, men who have sex with men; PG, phylogenetic group; IMD, Index of Multiple Deprivation.

men that was nested within travel-associated lineages, illustrating that shigellae have likely been introduced to the MSM population following recent travel to a high-risk region.

About one third of PG1 and PG3 isolates in our study were taken from PLWH, primarily acquired through sex between men, indicating the overlap between these epidemics. Of concern, MSM and PLWH were more likely than other cases to be treated with antimicrobials for their shigella infection, and MSM were also more likely to be hospitalized. The latter is consistent with a study from the USA that reported higher odds of severe shigellosis (hospitalisation, bacteremia or death associated with *S. flexneri*) in adult men compared to women, although sexual identity and behavior were not assessed (17).

HIV is a known risk factor for shigellosis (18, 19) and HIV-related immunosuppression has been associated with more severe illness prior to the introduction of highly active antiretroviral therapy (20–22). There were limited data in our study on CD4 count and HIV load, so we were unable to explore whether these factors were associated with shigellosis severity. Where data were available, most had an undetectable viral load and a high CD4 count. However, although the clinical implications are unclear, even with effective treatment there is evidence that gut mucosal immunity may not be fully restored (23, 24). The association between HIV status and antimicrobial use might also indicate more frequent health care attendance and thereby opportunities to collect stool specimens for microbiological investigations for PLWH. Clinicians might also be inclined to prescribe antimicrobials in PLWH to avoid further complications (25, 26).

We found a strong association between hospital admission and infection with *S. flexneri* serotype 2a that could reflect the presence of specific virulence determinants (27, 28). As MSM were more likely to be infected with *S. flexneri* serotype 2a than non-MSM, this could also partly explain more frequent hospital admissions among MSM.

Previous studies have found that MSM diagnosed with shigellosis are often coinfecting with or have a recent history of bacterial STIs (7). Azithromycin has been used for the treatment of many STIs and it is likely that off-target exposure from STI treatment has favored selection of azithromycin resistance in MSM-associated strains of *Shigella* spp. Although azithromycin is not the primary treatment for shigellosis (5), some MSM infected with azithromycin-resistant isolates were prescribed azithromycin, either alone or in combination with other antimicrobials. The high frequency of genotypic markers of azithromycin resistance among MSM isolates is concerning and indicates azithromycin is unsuitable for treating shigellosis in MSM. Furthermore, it highlights the need for a holistic approach to antimicrobial stewardship in this population that considers the long-term consequences of frequent antimicrobial exposure and bystander selection of resistance.

Unsurprisingly, we found the main exposure of MSM was recent sex with a man and that of non-MSM was recent travel to a high-risk region. However, 28% of MSM reported no recent sexual contact, which could suggest nonsexual transmission, a delay in symptom onset (incubation period greater than 4 days), relapse of a previously acquired chronic infection, or misreporting. Of note, a small number of isolates from PG1 and PG3 were from women, children, heterosexual men and other adult men who did not provide sexual identity or behavior information. It is possible that some of the adult men in these clades had sex with other men but did not disclose this due to perceived stigma (29, 30). Nonetheless, while transmission networks may overlap, there was no evidence of sustained transmission between networks of MSM and the wider community in England.

Our study has limitations. Questionnaire data were only available for HPTs who participated in the pilot and these covered geographical regions with proportionally larger MSM populations (31), thereby favoring questionnaire responses from MSM. Some antimicrobial treatment may have been prescribed for a coinfection (e.g., azithromycin for a bacterial STI). Insufficient sample size and the high level of correlation between independent variables prevented a multivariable analysis of the characteristics associated with clinical severity controlling for confounding. We only included cases presenting to health care who had a specimen referred to the reference

laboratory; a third of isolates cultured from stool samples at diagnostic hospital laboratories may not be referred and many less severe cases may remain undiagnosed (12). This under ascertainment of cases might have led to bias in our study because many factors are likely to influence whether an isolate is included, for instance health-seeking behavior and testing practices, which in turn may be influenced by severity of illness, age, the immune status of the individual or existing comorbidities (13, 32).

Our study illustrates the relevance and importance of sex between men as a route of transmission for *S. flexneri*, with multiple phylogenetically distinct lineages expanding clonally in MSM. Combining WGS, epidemiological and clinical data provides unique insights into *S. flexneri* transmission that can inform contact tracing, targeted prevention (e.g., washing hands and genitals before and after sex, using a barrier for risk practices and avoiding the use of shared sex toys [26, 33]) and appropriate referral for STI, HIV and blood-borne virus testing. We show that people will answer questions on sexual identity and behavior during public health follow-up and recommend they be included routinely in shigellosis investigations. Future studies should seek to explain why MSM experience more severe clinical outcomes. It is currently unclear whether this is related to the infecting pathogen, the gut microbiome or immune status of the individual, behavioral factors that influence the infectious dose, or a combination of these. Future studies would require a larger sample of cases to help distinguish the actual effect of each factor.

MATERIALS AND METHODS

Isolate collection. The UK Standards for Microbiology Investigations request that all isolates of *Shigella* spp. from diagnostic hospital laboratories are submitted to the national reference laboratory for species identification and molecular typing. In this study, we included all *S. flexneri* isolates referred to the national reference laboratory by diagnostic hospital laboratories in England between August 2015 and July 2017. Demographic data (name, date of birth, sex, postcode and foreign travel history) were available from laboratory request forms. Full details of the isolates used in this study have been reported previously (6).

Epidemiological and clinical data. We used data from two sources: a standardized exposure questionnaire used for public health follow-up of shigellosis cases (Supplementary File 1) and information collected as part of routine national HIV surveillance (34).

In the UK, shigellosis is statutorily notifiable, and all suspected cases are routinely contacted by a local health protection team (HPT) at PHE as part of public health follow-up and case management. The shigellosis questionnaire was designed to standardize and expand the information collected during case follow-up and was piloted between August 2015 and March 2017 in seven of the 21 HPTs in England (all three in London and four outside London) (6). Information was collected on sexual identity (cases aged ≥ 18 years), recent sexual contact (men aged ≥ 18 years), foreign travel, and food and water consumption (all within 4 days of symptom onset), clinical condition (including hospital admission and antimicrobial treatment), and whether the case belonged to a recognized risk group for onward transmission (e.g., food handler, health care worker, or having contact with children aged ≤ 5 years [10]). Data linkage to laboratory isolates used name, date of birth, sex, and postcode (6).

New HIV diagnoses among people aged ≥ 15 years are routinely reported to PHE on a voluntary basis by laboratories and clinicians from a variety of National Health Service (NHS) settings in England, Wales, and Northern Ireland (35). These data are supplemented with epidemiological and follow-up clinical data reported by all HIV outpatient clinics to create a national cohort of PLWH, known as the HARS. Data on new HIV diagnoses and care of PLWH in Scotland are submitted to PHE by Public Health Scotland and integrated with the national data set. Before submitting data to PHE, reporters convert the patient's surname to a soundex code (an anonymous identifier [36]). A hierarchical matching algorithm based on this soundex code, first initial, date of birth, postcode, and sex was used to link HARS to all *S. flexneri* isolates, including the subset with a questionnaire (18). HIV diagnosis date, probable route of exposure to HIV, most recent CD4 count and HIV load (within 3 months of *S. flexneri* diagnosis) were included in the final linked data set and all personal identifiers were removed.

WGS and sequencing analysis. Genomic DNA was extracted using the QiaSymphony DNA extraction platform (Qiagen) and WGS was performed using the Illumina HiSeq 2500 platform. Sequencing analysis was performed using a standardized pipeline (6, 37). Further details are provided in Supplementary File 2. Hierarchical single linkage clustering was performed on the pairwise single nucleotide polymorphism (SNP) distance matrix at descending distance thresholds (250, 100, 50, 25, 10, 5 and 0) (37). For phylogenetic analyses, recombinant regions of the genome were removed using Gubbins v2.0 (38) and RAxML v8.2.8 was used to create maximum-likelihood trees under the General Time Reversible model using up to 1000 bootstrap replicates (39). Tree annotation was performed using Interactive Tree Of Life (iTOL) v4.3 (40, 41).

Data analysis. We analyzed demographics and foreign travel history information alongside molecular data (phylogenetic inferences and genotypic markers of azithromycin resistance) for all *S. flexneri* cases included in the study. We also explored the characteristics of cases living with HIV. For cases with questionnaire data, characteristics were described for MSM (men who self-identified as gay or bisexual, or who reported

recent same-sex sexual contact), and all other cases combined (heterosexual men, women, and children <18 years old, herein 'non-MSM'). Differences between these two groups were assessed using the Chi-squared test (adult men who did not provide sexual identity or behavior information were excluded).

For *S. flexneri* cases with questionnaire data, we explored epidemiological, molecular and clinical characteristics associated with markers of clinical severity (25) using both univariable and age-adjusted logistic regression. These analyses were restricted to adult cases only. Characteristics associated with two different clinical outcomes were explored: hospital admission and antimicrobial use (as reported on the shigellosis questionnaire). Missing responses for these clinical outcomes were treated as absence of the specific outcome.

All analyses were restricted to isolates belonging to *S. flexneri* CC 245 as this was the dominant CC observed during the study period (92% of isolates) and all isolates from MSM belonged to CC245.

Ethical considerations. PHE has authority to collect and handle patient data for public health monitoring and infection control under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002. The PHE Caldicott Panel approved this analysis in June 2017. To ensure anonymity of PLWH, the final data set was irreversibly anonymised prior to analysis.

Data availability. FASTQ reads from all sequences can be found under the PHE Pathogens Bioproject (PRJNA315192) at the National Center for Biotechnology Information (NCBI) Read Archive: <https://www.ncbi.nlm.nih.gov/bioproject/315192>. The Short Read Archive accession numbers are available in the Supplementary Data File.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, XLSX file, 0.04 MB.

SUPPLEMENTAL FILE 2, PDF file, 0.3 MB.

ACKNOWLEDGEMENTS

We thank colleagues at the HPTs and Environmental Health Departments who were involved in the pilot of the standardized questionnaire, and members of the *Shigella* guidance working group. We also thank John Were and Rachel Glass for support with data collection, and Tracey Cairns and Krishna Gupta for data entry support.

We acknowledge the support of the steering committee members of the NIHR HPRU in Blood Borne and Sexually Transmitted Infections: Caroline Sabin (Director), John Saunders (PHE Lead), Catherine Mercer, Gwenda Hughes, Jackie Cassell, Greta Rait, Samreen Ijaz, Tim Rhodes, Kholoud Porter, Sema Mandal, and William Rosenberg.

FASTQ reads from all sequences can be found under the PHE Pathogens Bioproject (PRJNA315192) at the National Center for Biotechnology Information (NCBI) Read Archive: <https://www.ncbi.nlm.nih.gov/bioproject/315192>.

This research was conducted through the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at UCL in partnership with PHE, in collaboration with the London School of Hygiene and Tropical Medicine, and the NIHR HPRU in Gastrointestinal Infections at the University of Liverpool in partnership with PHE, in collaboration with the University of East Anglia, the University of Oxford and the Quadram Institute. H.D.M. and G.H. are affiliated with the NIHR HPRU in Blood Borne and Sexually Transmitted Infections. A.P., T.J.D., and C.J. are affiliated with the NIHR HPRU in Gastrointestinal Infections at the University of Liverpool. NRT is funded by Wellcome Trust grant 206194. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or PHE.

H.D.M., N.R.T., C.J., T.J.D., N.F., and G.H. designed the study. H.D.M. developed the study protocol and analyzed the data. Bioinformatic analyses were performed by H.D.M. and A.P., with advice from T.J.D. P.K. performed the HIV data linkage. All authors contributed to the interpretation of the data. H.D.M. wrote the first draft of the manuscript and all authors reviewed, critiqued, and offered comments on the text and approved the final version submitted for publication.

We declare no conflicts of interest.

REFERENCES

1. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. 1999. Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. *Bull World Health Organ* 77:651–666.

2. Global Burden of Disease (GBD) Diarrhoeal Diseases Collaborators. 2017. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis* 17:909–948. [https://doi.org/10.1016/S1473-3099\(17\)30276-1](https://doi.org/10.1016/S1473-3099(17)30276-1).
3. Mitchell H, Hughes G. 2018. Recent epidemiology of sexually transmissible enteric infections in men who have sex with men. *Curr Opin Infect Dis* 31:50–56. <https://doi.org/10.1097/QCO.0000000000000423>.
4. Simms I, Field N, Jenkins C, Childs T, Gilbert VL, Dallman TJ, Mook P, Crook PD, Hughes G. 2015. Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men—*Shigella flexneri* and *S. sonnei* in England, 2004 to end of February 2015. *Euro Surveill* 20. <https://doi.org/10.2807/1560-7917.ES2015.20.15.21097>.
5. Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, Gilbert VL, Zittermann S, Allen VG, Howden BP, Tomita T, Valcanis M, Harris SR, Connor TR, Sintchenko V, Howard P, Brown JD, Petty NK, Gouali M, Thanh DP, Keddy KH, Smith AM, Talukder KA, Faruque SM, Parkhill J, Baker S, Weill F-X, Jenkins C, Thomson NR. 2015. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. *Lancet Infect Dis* 15:913–921. [https://doi.org/10.1016/S1473-3099\(15\)00002-X](https://doi.org/10.1016/S1473-3099(15)00002-X).
6. Mitchell HD, Mikhail AFW, Painset A, Dallman TJ, Jenkins C, Thomson NR, Field N, Hughes G. 2019. Use of whole-genome sequencing to identify clusters of *Shigella flexneri* associated with sexual transmission in men who have sex with men in England: a validation study using linked behavioural data. *Microb Genom* 5. <https://doi.org/10.1099/mgen.0.000311>
7. Gilbert VL, Simms I, Jenkins C, Furegato M, Gobin M, Oliver I, Hart G, Gill ON, Hughes G. 2015. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with *Shigella flexneri* 3a in England and Wales. *Sex Transm Infect* 91:598–602. <https://doi.org/10.1136/sextrans-2015-052014>.
8. Marcus U, Zucs P, Bremer V, Hamouda O, Prager R, Tschaepe H, Futh U, Kramer M. 2004. Shigellosis—a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. *Int J STD AIDS* 15: 533–537. <https://doi.org/10.1258/0956462041558221>.
9. O'Sullivan B, Delpech V, Pontivivo G, Karagiannis T, Marriott D, Harkness J, McAnulty JM. 2002. Shigellosis linked to sex venues, Australia. *Emerg Infect Dis* 8:862–864. <https://doi.org/10.3201/eid0808.010534>.
10. Public Health England and the Chartered Institute of Environmental Health. Recommendations for the public health management of gastrointestinal infections: principles and practice. 2020. Available at: <https://www.gov.uk/government/publications/gastrointestinal-infections-guidance-for-public-health-management>. Accessed 1st Feb 2020.
11. McDonnell J, Dallman T, Atkin S, Turbitt DA, Connor TR, Grant KA, Thomson NR, Jenkins C. 2013. Retrospective analysis of whole genome sequencing compared to prospective typing data in further informing the epidemiological investigation of an outbreak of *Shigella sonnei* in the UK. *Epidemiol Infect* 141:2568–2575. <https://doi.org/10.1017/S0950268813000137>.
12. Public Health England. 2017. Laboratory surveillance of non-travel associated *Shigella* spp. infection in adult males, England: 2004 to 2017. Health Protection Report 11.
13. Mook P, Gardiner D, Kanagarajah S, Kerac M, Hughes G, Field N, McCarthy N, Rawlings C, Simms I, Lane C, Crook PD. 2018. Use of gender distribution in routine surveillance data to detect potential transmission of gastrointestinal infections among men who have sex with men in England. *Epidemiol Infect* 146:1468–1477. <https://doi.org/10.1017/S0950268818001681>.
14. Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, Weill F-X, Lefevre S, Tourdjman M, Hughes G, Jenkins C, Thomson N. 2018. Genomic epidemiology of *Shigella* in the United Kingdom shows transmission of pathogen sublineages and determinants of antimicrobial resistance. *Sci Rep* 8:7389. <https://doi.org/10.1038/s41598-018-25764-3>.
15. Dallman TJ, Chattaway MA, Mook P, Godbole G, Crook PD, Jenkins C. 2016. Use of whole-genome sequencing for the public health surveillance of *Shigella sonnei* in England and Wales, 2015. *J Med Microbiol* 65: 882–884. <https://doi.org/10.1099/jmm.0.000296>.
16. Chattaway MA, Greig DR, Gentle A, Hartman HB, Dallman TJ, Jenkins C. 2017. Whole-genome sequencing for national surveillance of *Shigella flexneri*. *Front Microbiol* 8:1700. <https://doi.org/10.3389/fmicb.2017.01700>.
17. McCrickard LS, Crim SM, Kim S, Bowen A. 2018. Disparities in severe shigellosis among adults - Foodborne diseases active surveillance network, 2002–2014. *BMC Public Health* 18:221. <https://doi.org/10.1186/s12889-018-5115-4>.
18. Mohan K, Hibbert M, Rooney G, Canvin M, Childs T, Jenkins C, Simms I, Kirwan P, Delpech V, Yin Z, Hughes G, Field N. 2018. What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission? *Sex Transm Infect* 94:67–71. <https://doi.org/10.1136/sextrans-2016-052962>.
19. Aragón TJ, Vugia DJ, Shallow S, Samuel MC, Reingold A, Angulo FJ, Bradford WZ. 2007. Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. *Clin Infect Dis* 44:327–334. <https://doi.org/10.1086/510593>.
20. Blaser MJ, Hale TL, Formal SB. 1989. Recurrent shigellosis complicating human immunodeficiency virus infection: failure of pre-existing antibodies to confer protection. *Am J Med* 86:105–107. [https://doi.org/10.1016/0002-9343\(89\)90239-8](https://doi.org/10.1016/0002-9343(89)90239-8).
21. Simor AE, Poon R, Borczyk A. 1989. Chronic *Shigella flexneri* infection preceding development of acquired immunodeficiency syndrome. *J Clin Microbiol* 27:353–355. <https://doi.org/10.1128/jcm.27.2.353-355.1989>.
22. Mandell W, Neu H. 1986. *Shigella* bacteremia in adults. *JAMA* 255: 3116–3117. <https://doi.org/10.1001/jama.1986.03370220078021>.
23. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M. 2012. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. *PLoS Pathog* 8:e1002506. <https://doi.org/10.1371/journal.ppat.1002506>.
24. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M. 2006. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. *PLoS Med* 3:e484. <https://doi.org/10.1371/journal.pmed.0030484>.
25. Farthing M, Feldman R, Finch R, Fox R, Leen C, Mandal B, Moss P, Nathwani D, Nye F, Percival A, Read R, Ritchie L, Todd WTA, Wood M. 1996. The management of infective gastroenteritis in adults: a consensus statement by an expert panel convened by the British Society for the Study of Infection. *J Infect* 33:143–152. [https://doi.org/10.1016/S0163-4453\(96\)92057-5](https://doi.org/10.1016/S0163-4453(96)92057-5).
26. Clutterbuck D, Asboe D, Barber T, Emerson C, Field N, Gibson S, Hughes G, Jones R, Murchie M, Nori AV, Rayment M, Sullivan A. 2018. 2016 United Kingdom national guideline on the sexual health care of men who have sex with men. *Int J STD AIDS* 95646241774689. <https://doi.org/10.1177/0956462417746897>.
27. Connor TR, Barker CR, Baker KS, Weill F-X, Talukder KA, Smith AM, Baker S, Gouali M, Pham Thanh D, Jahan Azmi I, Dias da Silveira W, Semmler T, Wieler LH, Jenkins C, Cravioto A, Faruque SM, Parkhill J, Wook Kim D, Keddy KH, Thomson NR. 2015. Species-wide whole genome sequencing reveals historical global spread and recent local persistence in *Shigella flexneri*. *Elife* 4:e07335. <https://doi.org/10.7554/eLife.07335>.
28. Noriega FR, Liao FM, Formal SB, Fasano A, Levine MM. 1995. Prevalence of *Shigella* enterotoxin 1 among *Shigella* clinical isolates of diverse serotypes. *J Infect Dis* 172:1408–1410. <https://doi.org/10.1093/infdis/172.5.1408>.
29. Geary RS, Tanton C, Erens B, Clifton S, Prah P, Wellings K, Mitchell KR, Datta J, Gravningen K, Fuller E, Johnson AM, Sonnenberg P, Mercer CH. 2018. Sexual identity, attraction and behaviour in Britain: the implications of using different dimensions of sexual orientation to estimate the size of sexual minority populations and inform public health interventions. *PLoS One* 13:e0189607. <https://doi.org/10.1371/journal.pone.0189607>.
30. Reback CJ, Larkins S. 2010. Maintaining a heterosexual identity: sexual meanings among a sample of heterosexually identified men who have sex with men. *Arch Sex Behav* 39:766–773. <https://doi.org/10.1007/s10508-008-9437-7>.
31. Public Health England. Producing modelled estimates of the size of the lesbian, gay and bisexual (LGB) population of England. 2017. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/585349/PHE_Final_report_FINAL_DRAFT_14.12.2016NB_230117v2.pdf (Accessed 19th February 2019).
32. Tam CC, Rodrigues LC, O'Brien SJ. 2003. The study of infectious intestinal disease in England: what risk factors for presentation to general practice tell us about potential for selection bias in case-control studies of reported cases of diarrhoea. *Int J Epidemiol* 32:99–105. <https://doi.org/10.1093/ije/dyg007>.
33. Public Health England. *Shigella*: leaflet and poster for men who have sex with men. Available from: <https://www.gov.uk/government/publications/shigella-leaflet-and-poster>. [Accessed 16th November 2019].
34. Public Health England. HIV surveillance systems. Available from: <https://www.gov.uk/guidance/hiv-surveillance-systems> [Accessed 16th November 2019].
35. Rice BD, Yin Z, Brown AE, Croxford S, Conti S, De Angelis D, Delpech VC. 2017. Monitoring of the HIV epidemic using routinely collected data: the case of the United Kingdom. *AIDS Behav* 21:83–90. <https://doi.org/10.1007/s10461-016-1604-6>.
36. Mortimer JY, Salathiel JA. 1995. "Soundex" codes of surnames provide confidentiality and accuracy in a national HIV database. *Commun Dis Rep CDR Rev* 5:R183–6.

37. Dallman T, Ashton P, Schafer U, Jironkin A, Painset A, Shaaban S, Hartman H, Myers R, Underwood A, Jenkins C, Grant K. 2018. SnapperDB: a database solution for routine sequencing analysis of bacterial isolates. *Bioinformatics* 34:3028–3029. <https://doi.org/10.1093/bioinformatics/bty212>.
38. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* 43:e15. <https://doi.org/10.1093/nar/gku1196>.
39. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* 30:1312–1313. <https://doi.org/10.1093/bioinformatics/btu033>.
40. Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. *Nucleic Acids Res* 44:W242–W245. <https://doi.org/10.1093/nar/gkw290>.
41. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res.* 47:W256–259. <https://doi.org/10.1093/nar/gkz239>.